A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma.
Liang Q, Gong M, Zou JH, Luo MY, Jiang LL, Wang C, Shen NX, Zhang MC, Xu L, Lei HM, Zhang KR, Zhang R, Zhuang G, Zhu L, Chen HZ, Zhou L, Shen Y.
Liang Q, et al. Among authors: zhang mc, zhang kr, zhang r.
Drug Resist Updat. 2023 May;68:100957. doi: 10.1016/j.drup.2023.100957. Epub 2023 Mar 16.
Drug Resist Updat. 2023.
PMID: 36990047
Free article.